PHD at Weizmann Institute, Rehovot, Israel
Dr. Katzav possesses a broad background in molecular and cellular biology of cancer and immunology, with specific expertise in signal transduction processes. Her research focuses on a comprehensive approach combining cellular and biochemical biology techniques, utilizing unique animal models created in her laboratory. As the scientist who identified, named, and characterized Vav1, she has a deep understanding of its physiological function and role in human cancer. Dr. Katzav is known as “Ms. Vav” among her colleagues and has built a strong team of students and collaborators. Despite her role as Vice Dean for Teaching and Education, she is dedicated to advancing cancer research.
Professional Profiles
Based on the information provided about Shulamit Katzav, here’s an evaluation for the Research for Best Researcher Award:
Strengths for the Award
Research Contributions: Shulamit Katzav has made significant contributions to cancer research, particularly in signal transduction processes. Her identification and characterization of the Vav1 gene and its role in human cancer are notable achievements.
Innovative Work: Katzav’s development of novel animal models and her comprehensive approach combining cellular and biochemical biology are indicative of innovative research.
Leadership and Service: She has held various leadership roles, including serving as Vice Dean for Education, Chairperson of multiple departments, and having a strong track record of service in academic and research committees.
Recognition and Awards: Katzav has received several travel awards and fellowships from prestigious organizations, reflecting her recognition in the scientific community.
Educational Contributions: Her involvement in curriculum development and teaching highlights her commitment to education and mentorship in the field.
Areas for Improvement
Broader Impact: While her research is impactful within cancer research, further efforts to translate her findings into clinical applications or broader therapeutic approaches could enhance her profile.
Public Engagement: Increasing visibility and engagement with the public and stakeholders outside the academic community could help in broader dissemination of her research impact.
Interdisciplinary Work: Exploring interdisciplinary collaborations beyond cancer research could offer new insights and applications of her work.
Diversity and Inclusion: Focusing on diversity and inclusion within her research team and outreach efforts could enhance the overall impact and inclusivity of her work.
Academic Background
1980-1984: Ph.D. in Cell Biology, Weizmann Institute, Rehovot, Israel 1973-1976: M.Sc. in Biology, Faculty of Medicine, Hebrew University, Jerusalem, Israel 1970-1973: B.Sc. in Biology, Hebrew University, Jerusalem, Israel
Professional Appointments
1984-1987: Post-doctorate, National Cancer Institute, Frederick, Maryland 1987-1989: Developmental Oncology Section, Gene Expression in Eukaryotes Section, National Cancer Institute – Frederick Cancer Research Facility, Frederick, Maryland 1989-1992: Visiting Scientist, Department of Biochemistry, St. Jude Children’s Research Hospital, Memphis, Tennessee 1993-1995: Associate Professor, Departments of Oncology and Experimental Medicine, Faculty of Medicine, McGill University, Montreal, Quebec 1995-2013: Associate Professor, Department of Cancer Research & Developmental Biology, Faculty of Medicine, The Hebrew University of Jerusalem, Israel
Awards and Honors
1980: Transplantation Meeting – Travel Award, Boston, Mass. 1982: Fellowship from the Union International Centre Cancer, Basel, Switzerland; Travel Award, Brighton, England 1983: Travel Award from NATO and the Israeli Cancer Society, Korfu, Greece 1984: Bat-Sheva Seminar Meeting on Metastasis – Travel Award, Tiberias, Israel 1985: Post-doctoral Fellowship from the Rothschild Foundation 1986: International Meeting on Metastasis – Travel Awards, Eilat, Israel; Vitoria, Spain 1995: Lady Davis Fellowship Trust-Mini-Sabbatical, Hebrew University Jerusalem, Israel 1996: Faculty of Medicine – Distinguished Lecturer
Conclusion
Shulamit Katzav is a strong candidate for the Research for Best Researcher Award based on her significant research achievements, innovative work, and leadership in her field. To further enhance her suitability, she might focus on expanding the broader impact of her research, increasing public engagement, and exploring interdisciplinary and inclusive approaches. Overall, her extensive contributions and recognized expertise make her a compelling candidate for this prestigious award.
Publications
- Role of Vav1, a hematopoietic signal transduction molecule, as an adaptor protein in health and disease, Publication date: 2023.
- Unraveling the Oncogenic Potential of VAV1 in Human Cancer: Lessons from Mouse Models, Publication date: 2023.
- Vav1 promotes b-cell lymphoma development, Publication date: 2022.
- Vav1 accelerates Ras-driven lung cancer and modulates its tumor microenvironment., Publication date: 2022.
- PO-196 Vav1 and Mutant K-Ras synergize in pancreatic ductal adenocarcinoma development: lessons from mouse models, Publication date: 2018.
- PO-135 Analysis of the transforming activity of human cancer identified Vav1 mutants prove its classification as an oncogene, Publication date: 2018.
- Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice, Publication date: 2020.
- Vav1 mutations: What makes them oncogenic?, Publication date: 2020.
-
- Guanine nucleotide exchange factors for RhoGTPases: good therapeutic targets for cancer therapy?,
.